drugset / Trial / NCT07827742
Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease
Phase 2
Not yet recruiting
120 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether Rituximab is safe and effective as a maintenance strategy in individuals with stabilized systemic sclerosis in adults.
Timeline
- Start
- 2026-10
- Primary completion
- 2030-05
- Completion
- 2031-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 500 mg | Intravenous |